Abiomed Inc. (NSDQ:ABMD) is ringing Wall Street’s bell in more ways than one today, with shares jumping nearly 25 percent on strong third-quarter results and CEO Michael Minogue preparing to ring the NASDAQ exchange’s closing bell this afternoon.

The Danvers, Mass.-based cardiac assist device maker said sales jumped nearly 23 percent during the three months ended Dec. 31., to $27.2 million. That helped it pare losses to just $802,000, or 2 cents per share. Abiomed posted losses of $4.6 million, or 12 cents per share, on sales of $22.8 million during Q3 2010.

The news was received well on Wall Street, where Minogue is slated to ring the final gong later today. ABMD shares jumped 23 percent from yesterday’s closing price of $” title=”ABMD ticker”>10.12, before retreating slightly by mid-day.

Abiomed said sales of its workhorse Impella pump, with the number of commercial patients treated in the U.S. up 77 percent to 752. Impella re-orders were up 106 percent compared to last year and the company added 29 new hospital customers during the quarter.

The good news — and the prospect of more of the same ahead — led Abiomed officials to boost their fiscal 2011 sales guidance to between $99 million and $101 million, up 16 percent to 18 percent from $93 million to $97 million.

“Abiomed’s momentum continues to grow with best-ever results for revenue, gross margin, operating cash flow and number of patients supported,” Minogue said in prepared remarks. “Today, Abiomed is proud to report to the shareholders that our innovative company is now generating cash flow.”